Medicines labeled for the same conditions
Alternatives to atezolizumab
16 other medicines are given the same way (intravenous) and in the same FDA class as atezolizumab or labeled mainly for the same use (lung cancer); 2 are in its class, programmed death receptor-1 blocking antibodies: nivolumab and pembrolizumab; the others include 2 topoisomerase inhibitors, 2 ctla-4-directed blocking antibodies and 1 folate analog metabolic inhibitor (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as atezolizumab?
Lung cancer lists all 55 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Atezolizumabprogrammed death receptor-1 blocking antibody | this medicine | none listed | n/a | No | No current entry |
| Nivolumabprogrammed death receptor-1 blocking antibody · same class | Lung cancer | none listed | n/a | No | No current entry |
| Pembrolizumabprogrammed death receptor-1 blocking antibody · same class | Lung cancer | none listed | n/a | No | No current entry |
| Pemetrexedfolate analog metabolic inhibitor | Lung cancer | 15 labelers | n/a | No | A presentation being discontinued |
| Etoposidetopoisomerase inhibitor | Lung cancer | 5 labelers | n/a | Yes | No current entry |
| Topotecantopoisomerase inhibitor | Lung cancer | 4 labelers | n/a | Yes | No current entry |
| Durvalumabprogrammed death ligand-1 blocker | Lung cancer | none listed | n/a | No | No current entry |
| Ipilimumabctla-4-directed blocking antibody | Lung cancer | none listed | n/a | No | No current entry |
| Ramucirumabvascular endothelial growth factor receptor 2 antagonist | Lung cancer | none listed | n/a | No | No current entry |
| Telisotuzumab vedotin | Lung cancer | none listed | n/a | No | No current entry |
| Tremelimumabctla-4-directed blocking antibody | Lung cancer | none listed | n/a | No | No current entry |
| Vinorelbinevinca alkaloid | Lung cancer | 2 labelers | n/a | Yes | No current entry |
| Zenocutuzumab | Lung cancer | none listed | n/a | Yes | No current entry |
| Amivantamab | Lung cancer | none listed | n/a | No | No current entry |
| Cemiplimab | Lung cancer | none listed | n/a | No | No current entry |
| Datopotamab deruxtecan | Lung cancer | none listed | n/a | No | No current entry |
| Lurbinectedinalkylating drug | Lung cancer | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Atezolizumab: the full record
- label, generics, price, shortages, recalls